FibroBiologics' Cell Therapy Trial Targets Stubborn Diabetic Wounds

HOUSTON, TX – June 16, 2026 – FibroBiologics (Nasdaq: FBLG) has officially moved its most advanced science from the laboratory into the lives of patients. The Houston-based biotech company announced that the first patients have been dosed in its Phase 1/2 clinical trial for CYWC628, a novel cell-based therapy aimed at treating diabetic foot ulcers (DFUs). This milestone is more than a procedural step; it represents a critical test for a therapeutic approach that seeks to fundamentally rebuild, rather than simply manage, one of diabetes' most devastating complications.

For investors and industry watchers, the initiation of human trials is a pivotal moment that begins to answer the core question of commercialization: can a promising technology translate into a safe, effective, and manufacturable product? With CYWC628, FibroBiologics is betting on the power of fibroblasts—the body’s own master builders of tissue—to succeed where other treatments have fallen short.

The Crippling Cost of a Silent Epidemic

To understand the significance of this trial, one must first grasp the grim reality of diabetic foot ulcers. These chronic, non-healing wounds are not a rare side effect; they are a common and life-altering complication, with individuals having a lifetime risk as high as 34%. Globally, this translates to an estimated 33 million people suffering from these debilitating sores.

The consequences are severe. DFUs are the leading cause of non-traumatic lower-extremity amputations. The five-year mortality rate for a patient with a DFU can be as high as 70%, a stark figure that surpasses many forms of cancer. The economic burden is equally staggering. In the United States alone, the cost of treating a single DFU episode can exceed $50,000, and the annual healthcare expenditure for a patient with a DFU is often more than triple that of a patient with diabetes but without the complication. Current standard-of-care—involving wound cleaning, dressings, and offloading pressure—is often a battle of containment, not cure, with recurrence rates reaching 65% within five years.

This high rate of failure highlights a significant unmet medical need and a market desperate for innovation. Existing therapies primarily focus on managing the wound environment, but often fail to address the underlying biological deficit in chronic wounds where the body's natural healing mechanisms have stalled.

Architects of Repair: A New Biological Blueprint

FibroBiologics aims to reboot this stalled process. Their candidate, CYWC628, is an allogeneic therapy composed of human dermal fibroblast spheroids. In healthy healing, fibroblasts are the crucial cells that migrate to a wound, secrete collagen and other extracellular matrix components to form new tissue, and orchestrate the entire repair and remodeling process. They are, as the company's CEO puts it, the “body's own architects of repair.”

“Initiating treatment in our first patients marks the moment our science transitions from the laboratory into the lives of the people in need,” said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. “CYWC628 is designed to restore the underlying biology that chronic wounds have lost rather than managing symptoms.”

By topically applying a concentrated dose of these highly active cells to the wound, the therapy is designed to re-establish a pro-healing environment, providing the necessary growth factors and structural components to kickstart the patient's own repair mechanisms. Preclinical data has suggested this approach could significantly accelerate wound healing. The ongoing Phase 1/2 trial, a randomized study involving up to 120 patients in Australia, will provide the first human data on whether this biological blueprint can deliver on its promise. The study will compare two different doses of CYWC628 against the standard of care, measuring wound closure rates and safety over a 12-week period.

De-Risking the Path to Market

A brilliant scientific concept is worthless if the product cannot be manufactured reliably and at scale. This is a notorious valley of death for many cell therapies. FibroBiologics appears to be acutely aware of this, tackling the manufacturing challenge in parallel with its clinical progress. The company announced that product from its second Good Manufacturing Practice (GMP) run has been released for shipment to trial sites in Australia. Furthermore, the first two batches of a third GMP run are already complete.

This is a crucial commercialization insight. Demonstrating reproducible manufacturing is a significant de-risking event for the company and its investors. It signals that the complex biological process of growing and formulating living cells into a therapeutic product is under control and can support not only the current trial but potential future, larger studies.

“Producing consecutive GMP runs of CYWC628 demonstrates that our fibroblast manufacturing platform is reproducible and ready to supply the ongoing clinical trial and beyond,” stated Hamid Khoja, Ph.D., Chief Scientific Officer. “This consistency is foundational. It provides us confidence both in the integrity of the product reaching patients and our ability to scale for clinical use.”

A Platform for the Future?

While the immediate focus is on diabetic foot ulcers, FibroBiologics' strategy extends far beyond a single indication. The company holds an expansive intellectual property portfolio of over 270 issued and pending patents, covering the use of fibroblasts for conditions as diverse as multiple sclerosis, disc degeneration, osteoporosis, and even cancer. This suggests that CYWC628 is not just a product, but a proof-of-concept for a broad therapeutic platform.

Success in the DFU trial could validate the entire fibroblast-based approach, opening the door to a pipeline of regenerative therapies. The company, which went public in early 2024, is positioning itself as a leader in a new generation of cell therapy. Recent patent filings for an oral fibroblast delivery system for GI disorders and a patent issuance for an osteoporosis therapy underscore this long-term ambition. For now, all eyes are on the progress in Australia, where the simple act of healing a wound could lay the foundation for a new era in regenerative medicine.